ARMSTRONG, Christopher, G.,KIM, Kevin, J.,PHAM, Lisa Maria Lucia,PARK, Eunhye,ZHONG, Zhong,HUANG, Guanyi,WU, Joseph, C.,ELMER, Sidney, Paul,VISUTHIKRAISEE, Viwat,CADAG, Eithon Michael, G.,FREEMAN, Tho
申请号：
HK19100316
公开号：
HK1257954A1
申请日:
2019.01.09
申请国别(地区):
HK
年份:
2019
代理人:
摘要：
This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′,4′,5′-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).
